Vol 6, No 3 (2013)
Prace poglądowe
Published online: 2013-10-11
Biopharmaceutics in nephrology
Forum Nefrologiczne 2013;6(3):139-149.
Abstract
Biopharmaceutics, are new group of therapeutics, designed and created by biotechnology. Their maintypes are recombinant proteins including monoclonal antibodies and fusion or chimeric proteins. They are characterized by specific and targeted actionand are mainly used in rheumatology, oncology, dermatology and gastroenterology. Recently, biopharmaceutics are increasingly used in nephrology and kidney transplantation. Up to now, rituximab — monoclonal, chimeric antibody against CD20, antigen present on lymphocytes is most commonly used in nephrology. It is used in treatment of many types primary glomerulonephritis, and, above all, in therapy of ANCA associated vasculitis and lupusnephritis.